Michael Cann, Director Generics at Actavis, has taken over as Chairman of the British Generic Manufacturer’s Association (BGMA).
Cann took over his new role at the Association’s AGM in London on 26 May. He replaces Kim Innes of Teva, who will serve as Vice Chair for a year.
He said he was honoured to accept the new role. “Our contribution is more than people realise,” he said. “It’s not just about reducing the drugs bill—though we provide two thirds of the NHS’s medicines at a fifth of the overall medicines cost. Generic competition also acts as a strong incentive for the research based industry to develop much needed, new, truly innovative medicines; and the security of supply of medicines to patients is enhanced when many manufacturers market the same product.”
Cann added that he looks forward to continuing the relationships that his predecessors enjoyed in Whitehall to the mutual benefit of patients, the NHS and the industry.
The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the UK.